Latest News

Sigachi Industries Limited officially inaugurated its new state-of-the-art Research and Development (R&D) Center in Hyderabad on June 18, 2025. This advanced facility is designed to consolidate API development and analytical capabilities under one roof, aiming to accelerate product development and enhance the company's responsiveness to global regulatory demands.

Key objectives of the Hyderabad R&D Center include:

• Strengthening API development and regulatory alignment by integrating advanced systems for seamless synthesis, analytics, and global filings.
• Fueling pipeline growth through a targeted investment of up to USD 1 million (approximately ₹8.3 crore) to support priority APIs and complex intermediates.
• Effectively focusing resources by aligning the pharma product portfolio to strategic therapeutic segments.
• Empowering a high-impact research team to lead development efforts for global markets.

Commenting on this development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, stated that the R&D Center is a "strategic asset" that will significantly strengthen the company's development capabilities and enable a swift response to market needs. He added that it reflects Sigachi's focus on building operational depth and creating long-term value for its customers, partners, and stakeholders in the evolving global pharmaceutical environment.

• Sigachi Industries has received Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for its upcoming Bulk Drugs, Drug Intermediates, and Specialty Chemicals facility at Orvakal, Kurnool District.
• The project is proposed on 25.09 acres at Guttapadu-Orvakal Node and falls under Category B1 of the EIA Notification, 2006.
• Environmental Clearance (EC) process will commence from 15th July 2025, with project development activities starting from 1st August 2025.
• The project aims to enhance API manufacturing capacity, support pipeline expansion, establish a strategically located facility with export potential, and contribute to 'Make in India'.
• Mr. Amit Raj Sinha, MD and CEO of Sigachi Industries, stated that this is a significant milestone to become a vertically integrated pharmaceutical manufacturing company and will help create scalable, sustainable, and compliant operations for global markets. He also mentioned that the facility will strengthen the product supply chain and enable faster commercialization.

Sigachi Industries Limited announced its audited financial results for the fourth quarter and financial year ended 31 March 2025, alongside a dividend recommendation and a strategic acquisition.

• Financial Highlights (Year Ended 31 March 2025):

  • Standalone Performance:
    • Revenue from operations stood at ₹407.83 crores, up from ₹317.50 crores in the previous fiscal year.
    • Profit for the period increased to ₹47.67 crores from ₹41.01 crores.
    • Basic Earnings Per Share (EPS) was ₹1.41, compared to ₹1.30 in the prior year.
  • Consolidated Performance:
    • Revenue from operations grew to ₹488.24 crores from ₹398.96 crores in the last fiscal year.
    • Profit for the period rose to ₹70.46 crores from ₹57.27 crores.
    • Basic EPS was ₹2.06, up from ₹1.81 previously.

• Quarterly Highlights (Quarter Ended 31 March 2025):

  • Standalone revenue from operations was ₹113.54 crores, a rise from ₹83.66 crores in the same quarter last year. However, standalone profit for the period decreased to ₹6.98 crores from ₹11.73 crores.
  • Consolidated revenue from operations increased to ₹128.20 crores from ₹104.13 crores. Consolidated profit for the period grew to ₹16.17 crores from ₹15.17 crores.

• Dividend Recommendation: The Board of Directors recommended a final dividend of Re. 0.10 per share for the financial year ended 31 March 2025, subject to approval by members at the Annual General Meeting.

• Strategic Acquisition: The company approved the acquisition of an additional 1,07,17,672 equity shares of ₹10 each in Trimax Bio Sciences Private Limited for ₹37.22 crores. This acquisition is through the conversion of advance/loan into equity and is subject to shareholder approvals. Trimax Bio Sciences, a subsidiary engaged in manufacturing pharmaceutical ingredients, bulk drugs, and intermediates, is an USFDA-approved facility. Sigachi Industries' holding in Trimax Bio Sciences will increase from 80% to 84.59% post-acquisition. Trimax Bio Sciences reported a turnover of ₹29 crores for FY 2024-25.

• Auditor Appointments: The Board approved the appointment of M/s. MPR & Associates as Cost Auditors and M/s. PSRV & Co. LLP as Internal Auditors for the financial year 2025-26. M/s. Aakanksha Dubey & Co. was appointed as Secretarial Auditor for five financial years starting from FY 2025-26.

• Audit Opinion: The Statutory Auditors, M/s. Yelamanchi & Associates Chartered Accountants, issued an unmodified/unqualified opinion on both standalone and consolidated audited financial results for the quarter and year ended 31 March 2025.

• Fund Utilization Status:

  • Out of the ₹89.70 crores from the IPO proceeds, ₹61.44 crores remain unutilized, specifically for expansion of MCC capacity at Jhagadia and establishing a CCS project at Dahej.
  • From the Preferential Issue through Convertible Warrants, the company received ₹217.82 crores until 8 February 2025, while ₹68.64 crores were not received from proposed investors. Out of the planned ₹286.45 crores, ₹197.91 crores have been utilized.